Beta Bionics Outlines Mint Launch by End of Q2 2027 and Raises Gross Margin Outlook for 2026
During its Q2 2026 earnings call, Beta Bionics (NASDAQ:BBNX) reported net sales of $32 million, representing a year-over-year growth of approximately 38%. The company attributed this increase to the expansion in new patient starts and an increasing installed base accessing iLet supplies through pharmacies. Management also announced plans for launching its Mint product by the end of Q2 2027. In addition, Beta Bionics raised its gross margin outlook for 2026 from a previous range to between 58.5% and 59.5%. This update reflects improved operational efficiency and cost management strategies as the company scales production.
Tickers: $BBNX
Topics: biotech medical_devices revenue_growth